Personalized Systemic Therapies in Hereditary Cancer Syndromes

被引：9

作者：

Mastrodomenico, Luciana ^{[1
]}

Piombino, Claudia ^{[1
]}

Ricco, Beatrice ^{[1
]}

Barbieri, Elena ^{[1
]}

Venturelli, Marta ^{[1
]}

Piacentini, Federico ^{[1
,2
]}

Dominici, Massimo ^{[1
,2
]}

Cortesi, Laura ^{[1
]}

Toss, Angela ^{[1
,2
]}

机构：

[1] Azienda Osped Univ Modena, Dept Oncol & Hematol, I-41124 Modena, Italy

[2] Univ Modena & Reggio Emilia, Dept Med & Surg Sci, I-41124 Modena, Italy

来源：

GENES | 2023年 / 14卷 / 03期

关键词：

hereditary cancer syndromes; BRCA; PALB2; MMR/MSI; VHL; RET; personalized therapy; MULTIPLE ENDOCRINE NEOPLASIA; HYPOXIA-INDUCIBLE FACTORS; METASTATIC BREAST-CANCER; HIPPEL-LINDAU DISEASE; RELAPSED OVARIAN-CANCER; GERMLINE MUTATIONS; HEDGEHOG PATHWAY; DOUBLE-BLIND; OPEN-LABEL; THYROID-CANCER;

D O I：

10.3390/genes14030684

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

Hereditary cancer syndromes are inherited disorders caused by germline pathogenic variants (PVs) that lead to an increased risk of developing certain types of cancer, frequently at an earlier age than in the rest of the population. The germline PVs promote cancer development, growth and survival, and may represent an ideal target for the personalized treatment of hereditary tumors. PARP inhibitors for the treatment of BRCA and PALB2-associated tumors, immune checkpoint inhibitors for tumors associated with the Lynch Syndrome, HIF-2a inhibitor in the VHL-related cancers and, finally, selective RET inhibitors for the treatment of MEN2-associated medullary thyroid cancer are the most successful examples of how a germline PVs can be exploited to develop effective personalized therapies and improve the outcome of these patients. The present review aims to describe and discuss the personalized systemic therapies for inherited cancer syndromes that have been developed and investigated in clinical trials in recent decades.

引用

页数：33

共 50 条

[31] Hereditary gastric and pancreatic cancer predisposition syndromes
Liz Leoz, Maria
Sanchez, Ariadna
Carballal, Sabela
Ruano, Lucia
Ocana, Teresa
Pellise, Maria
Castells, Antoni
Balaguer, Francesc
Moreira, Leticia
GASTROENTEROLOGIA Y HEPATOLOGIA, 2016, 39 (07): : 481 - 493
[32] Diagnostic Approach to Hereditary Colorectal Cancer Syndromes
Kalady, Matthew F.
Heald, Brandie
CLINICS IN COLON AND RECTAL SURGERY, 2015, 28 (04) : 205 - 214
[33] Hereditary Colorectal Cancer Syndromes and Genetic Testing
Macaron, Carole
Leach, Brandie H.
Burke, Carol A.
JOURNAL OF SURGICAL ONCOLOGY, 2015, 111 (01) : 103 - 111
[34] Surveillance of patients with hereditary gastrointestinal cancer syndromes
Moreira, Leticia
Castells, Antoni
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2016, 30 (06) : 923 - 935
[35] Hereditary Thyroid Cancer Syndromes and Genetic Testing
Rowland, Kathryn J.
Moley, Jeffrey F.
JOURNAL OF SURGICAL ONCOLOGY, 2015, 111 (01) : 51 - 60
[36] An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer
Yun, Karen M.
Cohen, Ezra E. W.
JCO ONCOLOGY PRACTICE, 2024, 20 (07) : 899 - 906
[37] The Evolving Personalized Landscape of Colorectal Cancer Therapies
Anker, Christopher J.
Buckstein, Michael H.
Chuong, Michael D.
Hawkins, Maria A.
Kharofa, Jordan
Raldow, Ann C.
Tait, Diana
Olsen, Jeffrey R.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (05): : 1255 - 1262
[38] Hereditary Syndromes of Neuroendocrine Tumours
Kaemmerer, D.
Posorski, N.
Hommann, M.
Baum, R. P.
Hoersch, D.
ZENTRALBLATT FUR CHIRURGIE, 2014, 139 (04): : 415 - 427
[39] Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes
Beebe-Dimmer, Jennifer L.
Kapron, Ashley L.
Fraser, Alison M.
Smith, Ken R.
Cooney, Kathleen A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1807 - +
[40] Oral mucosal stigmata in hereditary-cancer syndromes: From germline mutations to distinctive clinical phenotypes and tailored therapies
Ponti, Giovanni
Tomasi, Aldo
Manfredini, Marco
Pellacani, Giovanni
GENE, 2016, 582 (01) : 23 - 32

← 1 2 3 4 5 →